Cancer Drugs Fund Archives -

NICE clears use of GSK’s Jemperli in endometrial cancer

Phil Taylor Cancer Drugs Fund, endometrial cancer, GlaxoSmithKline, HEOR, Jemperli, market access, NICE, Oncology 0 Comment

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for

NICE clears use of GSK’s Jemperli in endometrial cancer

https://pharmaphorum.com/news/nice-clears-use-of-gsks-jemperli-in-endometrial-cancer/

Market Access/ News/ News

NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

Phil Taylor Bristol-Myers Squib, Cancer Drugs Fund, Inrebic, JAK inhibitor, myelofibrosis, NHS, NICE 0 Comment

After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year,

NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

https://pharmaphorum.com/news/nice-changes-tack-on-nhs-use-of-bms-myelofibrosis-drug-inrebic/

Market Access/ News/ News

NHS sets aside £340m for new Innovative Medicines Fund

Phil Taylor Cancer Drugs Fund, cell therapy, gene therapy, Innovative Medicines Fund, NHS, NHS England, rare disease 0 Comment

NHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of

NHS sets aside £340m for new Innovative Medicines Fund

https://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/

Market Access/ News/ News

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

Richard Staines breast cancer, cancer, Cancer Drugs Fund, Kisqali, market access, NICE 0 Comment

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

https://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/

Market Access/ News/ News

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

Phil Taylor Bristol-Myers Squib, Cancer Drugs Fund, Celgene, Haematology, multiple myeloma, NHS, NICE, Oncology, Revlimid, UK 0 Comment

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

https://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/

Market Access/ Views & Analysis/ Views and analysis

Future prospects for an Innovative Medicines Fund for England

Leela Barham Cancer Drugs Fund, CDF, Innovative Medicines Fund, NHS, UK 0 Comment

On the 12 December 2019, the UK general public voted for a further five years of Conservative government.

Future prospects for an Innovative Medicines Fund for England

https://pharmaphorum.com/views-analysis-market-access/future-prospects-for-an-innovative-medicines-fund-for-england/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

NICE’s track record in cancer drugs: the impact of the CDF and interim funding

Leela Barham cancer, Cancer Drugs Fund, CDF, HTA, NICE, NICE numbers at 20 0 Comment

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0

NICE’s track record in cancer drugs: the impact of the CDF and interim funding

https://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/

News/ Pharma Market Access/ Top stories/ UK & Europe

Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma

Richard Staines blood cancer, cancer, Cancer Drugs Fund, Johnson & Johnson, mantle cell lymphoma, UK market access 0 Comment

NICE suggests interim CDF funding while further data is gathered.

Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma

https://pharmaphorum.com/news/imbruvica-mantle-cell-lymphoma/

Cancer/ News/ Pharma Market Access/ UK & Europe

After a year’s delay, BMS seals Opdivo lung cancer deal with NICE

Richard Staines Bristol-Myers Squibb, cancer, Cancer Drugs Fund, lung cancer, market access, NICE, UK market access 0 Comment

Bristol-Myers Squibb will now challenge its rival, MSD’s Keytruda, in second line lung cancer treatment in England after

After a year’s delay, BMS seals Opdivo lung cancer deal with NICE

https://pharmaphorum.com/news/lung-cancer-patients-england-get-opdivo-bms-deal-nice/

Trending

Cancer Drugs Fund

Login